- The Wall Street Journal•27 days ago
Zymeworks Inc. has formed its seventh corporate alliance, a deal with Daiichi Sankyo Co. that deepens its pipeline of potential cancer therapeutics.
- Zacks•4 months ago
UCB (UCBJF) and Daiichi Sankyo announced that Vimpat was approved in Japan as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
Daiichi Sankyo Company, Limited (D4S.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
|Bid||0.00 x 50000|
|Ask||0.00 x 50000|
|Day's Range||20.90 - 21.50|
|52wk Range||16.57 - 23.15|
|1y Target Est||N/A|
|P/E Ratio (ttm)||19.56|
|Avg Vol (3m)||2|
|Dividend & Yield||N/A (N/A)|